Incyte (INCY) Current Deferred Revenue (2010 - 2016)
Incyte posted quarterly Current Deferred Revenue of $2.9 million for Q3 2016, down 77.69% year-on-year from $12.9 million in Q4 2015, and down 52.85% on a QoQ basis from $6.1 million in Q2 2016.
Incyte (INCY) has 7 years of Current Deferred Revenue data on file, last reported at $2.9 million in Q3 2016.
- For the quarter ending Q3 2016, Current Deferred Revenue fell 77.69% year-over-year to $2.9 million; the trailing twelve-month figure through Sep 2016 stood at $2.9 million (down 77.69% YoY), and the FY2015 full-year result was $12.5 million, down 2.86% from the prior year.
- Current Deferred Revenue for Q3 2016 stood at $2.9 million, down from $6.1 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $67.0 million in Q2 2012 and bottomed at $2.9 million in Q3 2016.
- The 5-year median for Current Deferred Revenue is $12.9 million (2014), against an average of $24.0 million.
- The widest annual swing landed in 2012, when Current Deferred Revenue plunged 91.03%; it then jumped 775.17% in 2013.
- A 5-year view of Current Deferred Revenue shows it stood at $66.1 million in 2012, then plunged by 80.49% to $12.9 million in 2013, then slipped by 0.08% to $12.9 million in 2014, then declined by 2.86% to $12.5 million in 2015, then sank by 77.08% to $2.9 million in 2016.
- The last three Current Deferred Revenue figures came in at $2.9 million (Q3 2016), $6.1 million (Q2 2016), and $9.3 million (Q1 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 2.87 Mn |
| Jun 30, 2016 | 6.08 Mn |
| Mar 31, 2016 | 9.30 Mn |
| Dec 31, 2015 | 12.51 Mn |
| Sep 30, 2015 | 12.86 Mn |
| Jun 30, 2015 | 12.86 Mn |
| Mar 31, 2015 | 12.86 Mn |
| Dec 31, 2014 | 12.88 Mn |
| Sep 30, 2014 | 12.88 Mn |
| Jun 30, 2014 | 12.89 Mn |
| Mar 31, 2014 | 12.89 Mn |
| Dec 31, 2013 | 12.89 Mn |
| Sep 30, 2013 | 25.50 Mn |
| Jun 30, 2013 | 39.03 Mn |
| Mar 31, 2013 | 52.55 Mn |
| Dec 31, 2012 | 66.08 Mn |
| Sep 30, 2012 | 66.97 Mn |
| Jun 30, 2012 | 66.98 Mn |
| Mar 31, 2012 | 6.01 Mn |
| Dec 31, 2011 | 66.97 Mn |
| Sep 30, 2011 | 66.97 Mn |
| Jun 30, 2011 | 66.98 Mn |
| Mar 31, 2011 | 66.98 Mn |
| Dec 31, 2010 | 66.97 Mn |